Lynn Rasmussen, Shalisa Sanders, Melinda Sosa, Sara McKellip, N Miranda Nebane, Yohanka Martinez-Gzegozewska, Andrew Reece, Pedro Ruiz, Anna Manuvakhova, Ling Zhai, Brooke Warren, Aliyah Curry, Qinghua Zeng, J Robert Bostwick, Paige N Vinson
{"title":"高通量应对 SARS-CoV-2 大流行。","authors":"Lynn Rasmussen, Shalisa Sanders, Melinda Sosa, Sara McKellip, N Miranda Nebane, Yohanka Martinez-Gzegozewska, Andrew Reece, Pedro Ruiz, Anna Manuvakhova, Ling Zhai, Brooke Warren, Aliyah Curry, Qinghua Zeng, J Robert Bostwick, Paige N Vinson","doi":"10.1016/j.slasd.2024.100160","DOIUrl":null,"url":null,"abstract":"<p><p>Four years after the beginning of the COVID-19 pandemic, it is important to reflect on the events that have occurred during that time and the knowledge that has been gained. The response to the pandemic was rapid and highly resourced; it was also built upon a foundation of decades of federally funded basic and applied research. Laboratories in government, pharmaceutical, academic, and non-profit institutions all played roles in advancing pre-2020 discoveries to produce clinical treatments. This perspective provides a summary of how the development of high-throughput screening methods in a biosafety level 3 (BSL-3) environment at Southern Research Institute (SR) contributed to pandemic response efforts. The challenges encountered are described, including those of a technical nature as well as those of working under the pressures of an unpredictable virus and pandemic.</p>","PeriodicalId":74806,"journal":{"name":"SLAS discovery : advancing life sciences R & D","volume":" ","pages":"100160"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A high-throughput response to the SARS-CoV-2 pandemic.\",\"authors\":\"Lynn Rasmussen, Shalisa Sanders, Melinda Sosa, Sara McKellip, N Miranda Nebane, Yohanka Martinez-Gzegozewska, Andrew Reece, Pedro Ruiz, Anna Manuvakhova, Ling Zhai, Brooke Warren, Aliyah Curry, Qinghua Zeng, J Robert Bostwick, Paige N Vinson\",\"doi\":\"10.1016/j.slasd.2024.100160\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Four years after the beginning of the COVID-19 pandemic, it is important to reflect on the events that have occurred during that time and the knowledge that has been gained. The response to the pandemic was rapid and highly resourced; it was also built upon a foundation of decades of federally funded basic and applied research. Laboratories in government, pharmaceutical, academic, and non-profit institutions all played roles in advancing pre-2020 discoveries to produce clinical treatments. This perspective provides a summary of how the development of high-throughput screening methods in a biosafety level 3 (BSL-3) environment at Southern Research Institute (SR) contributed to pandemic response efforts. The challenges encountered are described, including those of a technical nature as well as those of working under the pressures of an unpredictable virus and pandemic.</p>\",\"PeriodicalId\":74806,\"journal\":{\"name\":\"SLAS discovery : advancing life sciences R & D\",\"volume\":\" \",\"pages\":\"100160\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"SLAS discovery : advancing life sciences R & D\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.slasd.2024.100160\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"SLAS discovery : advancing life sciences R & D","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.slasd.2024.100160","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A high-throughput response to the SARS-CoV-2 pandemic.
Four years after the beginning of the COVID-19 pandemic, it is important to reflect on the events that have occurred during that time and the knowledge that has been gained. The response to the pandemic was rapid and highly resourced; it was also built upon a foundation of decades of federally funded basic and applied research. Laboratories in government, pharmaceutical, academic, and non-profit institutions all played roles in advancing pre-2020 discoveries to produce clinical treatments. This perspective provides a summary of how the development of high-throughput screening methods in a biosafety level 3 (BSL-3) environment at Southern Research Institute (SR) contributed to pandemic response efforts. The challenges encountered are described, including those of a technical nature as well as those of working under the pressures of an unpredictable virus and pandemic.